sorafenib has been researched along with transforming growth factor beta in 20 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (transforming growth factor beta) | Trials (transforming growth factor beta) | Recent Studies (post-2010) (transforming growth factor beta) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 49,119 | 560 | 17,610 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 18 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angelotti, U; Antonaci, S; Fransvea, E; Giannelli, G | 1 |
| Aburatani, H; Hirakawa, K; Iwata, C; Johansson, E; Kano, MR; Kiyono, K; Komuro, A; Matsumoto, Y; Miyazono, K; Miyoshi, H; Morishita, Y; Shirai, YT; Suzuki, HI; Watanabe, A; Yashiro, M | 1 |
| Caja, L; Campbell, JS; Fabregat, I; Fausto, N; Fernández-Rodriguez, CM; Fernando, J; Lledó, JL; Sancho, P | 1 |
| Alsinet, C; Barretina, J; Bruix, J; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Mazzaferro, V; Minguez, B; Newell, P; Savic, R; Schwartz, M; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC | 1 |
| Feng, M; Liu, X; Wang, Q; Wang, Z; Yu, T; Yuan, Y; Zhuang, H | 1 |
| Hui, KM; Ooi, LL; Xia, H | 1 |
| Dufour, JF; Erös de Bethlenfalva-Hora, C; Geier, A; Kettenbach, J; Mertens, JC; Piguet, AC; Schmitt, J; Terracciano, L; Weimann, R | 1 |
| Chen, CL; Dooley, S; Feldman, D; French, SW; Jeong, JH; Kashiwabara, C; Liu, JC; Machida, K; Mishra, L; Petrovic, L; Sher, L; Tsukamoto, H | 1 |
| Noguchi, S; Takizawa, H; Yamauchi, Y | 1 |
| Aoyagi, Y; Fujimaki, S; Hirose, Y; Kobayashi, T; Kubota, M; Matsuda, Y; Osawa, M; Sakata, J; Takamura, M; Wakai, T; Yamagiwa, S | 1 |
| Alvarez-Barrientos, A; Bertran, E; Cepeda, EB; Fabra, À; Fabregat, I; Fernández-Rodríguez, CM; Fernández-Salguero, P; Fernando, J; Giannelli, G; Malfettone, A; Raimondi, G; Sancho, P; Vilarrasa-Blasi, R | 1 |
| Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L | 1 |
| Llovet, JM; Torrecilla, S | 1 |
| Bandukwala, H; Belsúe, V; Casares, N; Coffer, PJ; Durántez, M; Gorraiz, M; Hervás-Stubbs, S; Lasarte, JJ; Lourenço, AR; Lozano, T; Oyarzábal, J; Prieto, J; Riezu-Boj, JI; Ruiz, M; Sarobe, P; Villanueva, L | 1 |
| Chen, YL; Ding, X; Gao, Z; Gu, T; Liu, W; Qu, M; Wang, W; Wu, X; Xu, L; Zhang, W | 1 |
| Han, C; Ungerleider, N; Wu, T; Yao, L; Zhang, J | 1 |
| Choi, HJ; Han, Z; Joo, Y; Kang, D; Oh, GH; Song, JJ | 1 |
| Antarianto, RD; Arozal, W; Louisa, M; Rahmaniah, R; Soetikno, V; Yuyuntia, Y | 1 |
| Chen, CL; Chung, CL; Kao, YC; Shiao, MS; Shu, CW; Sun, WC; Wang, SW | 1 |
| Afifi, AM; El-Houseini, ME; El-Husseiny, AM; Khalil, MA; Tabashy, RH | 1 |
2 review(s) available for sorafenib and transforming growth factor beta
| Article | Year |
|---|---|
Novel therapeutic strategies for fibrotic lung disease: a review with a focus on epithelial-mesenchymal transition.
Topics: Airway Remodeling; Animals; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Inflammation Mediators; Lung; Lung Diseases; Myofibroblasts; Niacinamide; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Respiratory Mucosa; Sorafenib; Stromal Cells; Transforming Growth Factor beta | 2014 |
New molecular therapies for hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Fibroblast Growth Factors; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sorafenib; Transforming Growth Factor beta | 2015 |
18 other study(ies) available for sorafenib and transforming growth factor beta
| Article | Year |
|---|---|
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transforming Growth Factor beta | 2008 |
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunohistochemistry; Lentivirus Infections; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Signal Transduction; Smad2 Protein; Sorafenib; Stomach Neoplasms; Thrombospondin 1; Transforming Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2009 |
Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autocrine Communication; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Knockdown Techniques; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2012 |
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Topics: Animals; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cluster Analysis; Female; Gene Expression Profiling; Genomics; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reproducibility of Results; Sorafenib; Transforming Growth Factor beta; Wnt Proteins; Wnt Signaling Pathway | 2012 |
Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Topics: Adult; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Down-Regulation; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2013 |
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; In Vitro Techniques; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Smad7 Protein; Sorafenib; Transforming Growth Factor beta; Up-Regulation | 2013 |
Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; Hepatocyte Growth Factor; Interleukin-10; Liver Neoplasms, Experimental; Macrophages; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; T-Lymphocytes; Transforming Growth Factor beta; Vascular Endothelial Growth Factors | 2014 |
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells.
Topics: AC133 Antigen; Adaptor Proteins, Signal Transducing; Animals; Antigens, CD; Antineoplastic Agents; Base Sequence; Carcinoma, Hepatocellular; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycoproteins; Homeodomain Proteins; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Nanog Homeobox Protein; Neoplastic Stem Cells; Niacinamide; Oncogenes; Peptides; Phenylurea Compounds; Phosphoproteins; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; Sirolimus; Smad Proteins; Sorafenib; Spheroids, Cellular; Toll-Like Receptor 4; Transcription Factors; Transcriptional Activation; Transforming Growth Factor beta; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2013 |
Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Treatment Failure; Treatment Outcome; Valproic Acid | 2014 |
A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Hyaluronan Receptors; Liver Neoplasms, Experimental; Mice, Nude; Niacinamide; Phenotype; Phenylurea Compounds; Sorafenib; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2015 |
Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.
Topics: Actins; Animals; Apoptosis; Cadherins; Cell Line; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Immunohistochemistry; Kidney Diseases; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Smad3 Protein; Sorafenib; Transforming Growth Factor beta; Ureteral Obstruction | 2015 |
Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
Topics: Animals; Antineoplastic Agents; CD40 Ligand; Cell Proliferation; CTLA-4 Antigen; Female; Forkhead Transcription Factors; Humans; Immunotherapy; Interferon-gamma; Interleukin-17; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Interleukin-6; Jurkat Cells; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; NFATC Transcription Factors; Niacinamide; Ovalbumin; Peptide Fragments; Phenylurea Compounds; Promoter Regions, Genetic; Receptors, Antigen, T-Cell; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2015 |
Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways.
Topics: Adult; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Female; Fibroblasts; Humans; Keloid; Male; Middle Aged; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sincalide; Smad Proteins; Sorafenib; Transforming Growth Factor beta; Young Adult | 2016 |
TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Quinolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Transforming Growth Factor beta | 2017 |
Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; RNA, Small Interfering; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2017 |
Alpha mangostin Inhibits Hepatic Stellate Cells Activation Through TGF-β/Smad and Akt Signaling Pathways: An in vitro Study in LX2.
Topics: Actins; Animals; Biomarkers; Cell Proliferation; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Ki-67 Antigen; Male; Niacinamide; Phenylurea Compounds; Plasminogen Activator Inhibitor 1; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Smad3 Protein; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Xanthones | 2018 |
Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Caveolae; Cell Line, Transformed; Cell Membrane; Dose-Response Relationship, Drug; Endocytosis; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; Male; Membrane Microdomains; Mice; Mice, Inbred C57BL; Mink; Rats; Receptor, Transforming Growth Factor-beta Type II; Sorafenib; Transforming Growth Factor beta; Treatment Outcome | 2018 |
Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Cytokines; Drug Therapy, Combination; Forkhead Transcription Factors; Hep G2 Cells; Humans; L-Lactate Dehydrogenase; Leukocytes, Mononuclear; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib; Taurine; Transforming Growth Factor beta | 2019 |